Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia
Metrics: PDF 1123 views | Full Text 1108 views | ?
Stacey J. Baker1, Stephen C. Cosenza1, M.V. Ramana Reddy1, and E. Premkumar Reddy1,2
1Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
2Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Stacey J. Baker, email: email@example.com
E. Premkumar Reddy, email: firstname.lastname@example.org
Keywords: rigosertib; RAS; hematopoiesis; myeloproliferative disorder
Received: January 04, 2019 Accepted: February 08, 2019 Published: March 08, 2019
Aberrant signaling triggered by oncogenic or hyperactive RAS proteins contributes to the malignant phenotypes in a significant percentage of myeloid malignancies. Of these, juvenile myelomonocytic leukemia (JMML), an aggressive childhood cancer, is largely driven by mutations in RAS genes and those that encode regulators of these proteins. The Mx1-cre kras+/G12D mouse model mirrors several key features of this disease and has been used extensively to determine the utility and mechanism of small molecule therapeutics in the context of RAS-driven myeloproliferative disorders. Treatment of disease-bearing KRASG12D mice with rigosertib (RGS), a small molecule RAS mimetic that is in phase II and III clinical trials for MDS and AML, decreased the severity of leukocytosis and splenomegaly and extended their survival. RGS also increased the frequency of HSCs and rebalanced the ratios of myeloid progenitors. Further analysis of KRASG12D HSPCs in vitro revealed that RGS suppressed hyperproliferation in response to GM-CSF and inhibited the phosphorylation of key RAS effectors. Together, these data suggest that RGS might be of clinical benefit in RAS-driven myeloid disorders.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.